CA2839420C - High affinity human antibodies to human cytomegalovirus (cmv) gb protein - Google Patents
High affinity human antibodies to human cytomegalovirus (cmv) gb protein Download PDFInfo
- Publication number
- CA2839420C CA2839420C CA2839420A CA2839420A CA2839420C CA 2839420 C CA2839420 C CA 2839420C CA 2839420 A CA2839420 A CA 2839420A CA 2839420 A CA2839420 A CA 2839420A CA 2839420 C CA2839420 C CA 2839420C
- Authority
- CA
- Canada
- Prior art keywords
- mab
- seq
- immunoreactive fragment
- cmv
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract description 37
- 102000004169 proteins and genes Human genes 0.000 title abstract description 34
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract description 3
- 241000701022 Cytomegalovirus Species 0.000 claims abstract description 53
- 210000004027 cell Anatomy 0.000 claims description 56
- 239000012634 fragment Substances 0.000 claims description 41
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 206010061598 Immunodeficiency Diseases 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 5
- 206010011831 Cytomegalovirus infection Diseases 0.000 abstract description 4
- 230000000069 prophylactic effect Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 210000003754 fetus Anatomy 0.000 abstract description 3
- 210000002826 placenta Anatomy 0.000 abstract description 2
- 230000035935 pregnancy Effects 0.000 abstract description 2
- 238000012546 transfer Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 29
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 102100029812 Protein S100-A12 Human genes 0.000 description 8
- 101710110949 Protein S100-A12 Proteins 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 5
- 102100029618 Rab-like protein 6 Human genes 0.000 description 5
- 101150076252 Rabl6 gene Proteins 0.000 description 5
- 101150117115 V gene Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 208000007569 Giant Cell Tumors Diseases 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 2
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100022662 Guanylyl cyclase C Human genes 0.000 description 1
- 101710198293 Guanylyl cyclase C Proteins 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- -1 cationic lipid Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000024697 human cytomegalovirus infection Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000004650 oncogenic pathway Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35549910P | 2010-06-16 | 2010-06-16 | |
| US61/355,499 | 2010-06-16 | ||
| PCT/US2011/040761 WO2011159938A2 (en) | 2010-06-16 | 2011-06-16 | High affinity human antibodies to human cytomegalovirus (cmv) gb protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2839420A1 CA2839420A1 (en) | 2011-12-22 |
| CA2839420C true CA2839420C (en) | 2023-06-13 |
Family
ID=45348879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2839420A Active CA2839420C (en) | 2010-06-16 | 2011-06-16 | High affinity human antibodies to human cytomegalovirus (cmv) gb protein |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9017668B2 (enExample) |
| EP (1) | EP2582389B1 (enExample) |
| JP (2) | JP6055763B2 (enExample) |
| KR (1) | KR101900435B1 (enExample) |
| CN (1) | CN103221063B (enExample) |
| AU (1) | AU2011268277B2 (enExample) |
| BR (1) | BR112012032182A2 (enExample) |
| CA (1) | CA2839420C (enExample) |
| IL (1) | IL223665B (enExample) |
| RU (1) | RU2613421C2 (enExample) |
| WO (1) | WO2011159938A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2542308T3 (es) * | 2008-03-10 | 2015-08-04 | Theraclone Sciences, Inc. | Composiciones y métodos para la terapia y diagnóstico de infecciones por citomegalovirus |
| JP5833565B2 (ja) | 2009-12-23 | 2015-12-16 | ４−アンティボディ・アクチェンゲゼルシャフト４−Ａｎｔｉｂｏｄｙ Ａｇ | ヒトサイトメガロウイルスに対する結合メンバー |
| KR101900435B1 (ko) * | 2010-06-16 | 2018-09-20 | 트렐리스 바이오싸이언스 인코포레이티드 | 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체 |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11440951B2 (en) | 2017-03-13 | 2022-09-13 | The Government Of The United States, As Represented By The Secretary Of The Army | Therapeutic antibodies to Marburg virus |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CN118465272B (zh) * | 2019-12-04 | 2025-08-19 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6642062B2 (en) | 1998-09-03 | 2003-11-04 | Trellis Bioinformatics, Inc. | Multihued labels |
| US20090042291A1 (en) | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
| US8420353B2 (en) | 2002-03-22 | 2013-04-16 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| US7427469B2 (en) * | 2002-11-05 | 2008-09-23 | Institut Pasteur | Method of treating cytomegalovirus with DC-SIGN blockers |
| RU2239453C2 (ru) * | 2002-12-03 | 2004-11-10 | Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" | Препарат иммуноглобулина человека против цитомегаловируса и способ его получения |
| US7595379B2 (en) * | 2003-05-30 | 2009-09-29 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
| US7413868B2 (en) | 2003-11-05 | 2008-08-19 | Trellis Bioscience, Inc. | Use of particulate labels in bioanalyte detection methods |
| ES2526343T3 (es) | 2004-06-03 | 2015-01-09 | Novimmune Sa | Anticuerpos anti-CD3 y métodos de uso de los mismos |
| WO2007094423A1 (ja) | 2006-02-15 | 2007-08-23 | Evec Incorporated | ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| JP2009531273A (ja) * | 2006-02-28 | 2009-09-03 | オンコセラピー・サイエンス株式会社 | 抗ＥｐｈＡ４抗体のエフェクター機能を用いて細胞を障害する方法 |
| CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| CA2657123A1 (en) | 2006-07-12 | 2008-01-17 | Trellis Bioscience, Inc. | Cellspottm applications |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| CN100575361C (zh) * | 2007-04-28 | 2009-12-30 | 中国人民解放军第三军医大学野战外科研究所 | 抗人巨细胞病毒包膜糖蛋白b的人源化单链抗体 |
| US20110171233A1 (en) * | 2007-08-22 | 2011-07-14 | Ribovax Biotechnologies S.A. | Antibodies Against Human Cytomegalovirus (HCMV) |
| RU2364627C2 (ru) * | 2007-11-06 | 2009-08-20 | Власик Татьяна Николаевна | Экспрессионный вектор для синтеза белков в клетках млекопитающих |
| JP2011517320A (ja) | 2008-03-03 | 2011-06-02 | ダイアックス コーポレーション | メタロプロテアーゼ９結合タンパク質およびメタロプロテアーゼ２結合タンパク質 |
| ES2542308T3 (es) | 2008-03-10 | 2015-08-04 | Theraclone Sciences, Inc. | Composiciones y métodos para la terapia y diagnóstico de infecciones por citomegalovirus |
| EP2352759B1 (en) * | 2008-07-16 | 2017-11-01 | Institute for Research in Biomedicine | Human cytomegalovirus neutralizing antibodies and use thereof |
| KR101900435B1 (ko) * | 2010-06-16 | 2018-09-20 | 트렐리스 바이오싸이언스 인코포레이티드 | 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체 |
-
2011
- 2011-06-16 KR KR1020137001220A patent/KR101900435B1/ko active Active
- 2011-06-16 US US13/162,497 patent/US9017668B2/en active Active
- 2011-06-16 CN CN201180038472.0A patent/CN103221063B/zh not_active Expired - Fee Related
- 2011-06-16 RU RU2013101769A patent/RU2613421C2/ru not_active IP Right Cessation
- 2011-06-16 BR BR112012032182A patent/BR112012032182A2/pt not_active IP Right Cessation
- 2011-06-16 AU AU2011268277A patent/AU2011268277B2/en active Active
- 2011-06-16 EP EP11796460.1A patent/EP2582389B1/en active Active
- 2011-06-16 CA CA2839420A patent/CA2839420C/en active Active
- 2011-06-16 JP JP2013515522A patent/JP6055763B2/ja active Active
- 2011-06-16 WO PCT/US2011/040761 patent/WO2011159938A2/en not_active Ceased
-
2012
- 2012-12-16 IL IL223665A patent/IL223665B/en active IP Right Grant
-
2015
- 2015-04-27 US US14/697,459 patent/US9688744B2/en active Active
-
2016
- 2016-10-07 JP JP2016198700A patent/JP2017038612A/ja active Pending
-
2017
- 2017-03-20 US US15/464,165 patent/US10030069B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011268277B2 (en) | 2016-10-27 |
| AU2011268277A2 (en) | 2013-07-25 |
| WO2011159938A2 (en) | 2011-12-22 |
| IL223665B (en) | 2020-01-30 |
| JP6055763B2 (ja) | 2016-12-27 |
| CN103221063A (zh) | 2013-07-24 |
| RU2613421C2 (ru) | 2017-03-16 |
| EP2582389A4 (en) | 2014-01-08 |
| RU2013101769A (ru) | 2014-07-27 |
| US10030069B2 (en) | 2018-07-24 |
| CA2839420A1 (en) | 2011-12-22 |
| EP2582389B1 (en) | 2018-02-21 |
| US20150252099A1 (en) | 2015-09-10 |
| CN103221063B (zh) | 2016-08-24 |
| AU2011268277A1 (en) | 2013-01-31 |
| US20120020980A1 (en) | 2012-01-26 |
| US9017668B2 (en) | 2015-04-28 |
| EP2582389A2 (en) | 2013-04-24 |
| BR112012032182A2 (pt) | 2016-10-25 |
| JP2017038612A (ja) | 2017-02-23 |
| WO2011159938A3 (en) | 2012-04-19 |
| KR20130086036A (ko) | 2013-07-30 |
| US20170204165A1 (en) | 2017-07-20 |
| JP2013531991A (ja) | 2013-08-15 |
| KR101900435B1 (ko) | 2018-09-20 |
| US9688744B2 (en) | 2017-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2839420C (en) | High affinity human antibodies to human cytomegalovirus (cmv) gb protein | |
| CN113354729B (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
| CA2703667C (en) | Anti-rsv g protein antibodies | |
| CN111333723B (zh) | 针对狂犬病病毒g蛋白的单克隆抗体及其用途 | |
| CN113045647B (zh) | 新冠病毒SARS-CoV-2的中和性抗体及其应用 | |
| CN113354730B (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
| US20240207401A1 (en) | Coronavirus antibody | |
| US20090004198A1 (en) | Human monoclonal antibody binding to human cytomegalovirus and its antigen binding portion | |
| CN118184774A (zh) | 中和SARS-CoV-2及变异株的全人源抗体及应用 | |
| CN116836269A (zh) | 抗呼吸道合胞病毒的单克隆抗体及其应用 | |
| CN116041494A (zh) | 一种针对SARS-CoV或SARS-CoV-2的单克隆抗体、其制备方法及应用 | |
| WO2025246679A1 (zh) | 一种广谱中和冠状病毒的抗体及其应用 | |
| CN114933649A (zh) | 抗水痘-带状疱疹病毒的抗体及其用途 | |
| CN119119256A (zh) | 一种乙型脑炎病毒和寨卡病毒的单克隆抗体及其应用 | |
| US20240228595A1 (en) | Methods for Monoclonal Antibody Generation | |
| CN115975019B (zh) | 一种抗新型冠状病毒的抗体及其用途 | |
| CN119421953A (zh) | 具有突变株交叉性的抗SARS－CoV－2人中和抗体及其抗原结合片段 | |
| JP2011050269A (ja) | 狂犬病ウイルスに対するヒト抗体ならびにその医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160606 |
|
| EEER | Examination request |
Effective date: 20160606 |
|
| EEER | Examination request |
Effective date: 20160606 |
|
| EEER | Examination request |
Effective date: 20160606 |
|
| EEER | Examination request |
Effective date: 20160606 |